1 Stem-Cell Spinout You Must Watch

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Nearly a year after Geron (Nasdaq: GERN  ) said it was shuttering its stem cell program, the biotech has a buyer if it wants.

Buyer being a relative term.

BioTime (NYSEMKT: BTX  ) agreed to take over the program, but Geron wouldn't get anything in return. The proposal is basically a spinout combining BioTime's and Geron's stem-cell assets. BioTime also plans to contribute $40 million worth of its stock, which would presumably be sold to fund the program. The new entity also plans to sell shares to raise additional capital.

Geron's shareholders would own 21.4% of the new company, which could increase to 45% if they purchase additional shares in the spinoff. BioTime is also willing to give Geron's shareholders warrants to buy shares of BioTime.

BioTime proposed the deal in a letter to Geron's shareholders encouraging them to push the board into approving the transaction. Not said, but implied, is that BioTime has probably run the deal (or something similar) by Geron's board, which must have rejected the offer. On Friday, Geron acknowledged BioTime's proposal and said the board would consider it.

My guess is the board won't accept the public offer. Geron's management decided that the cancer program is the most important thing, and this deal doesn't bring in any cash to help the program. Canceling the stem cell program certainly helped with the cash burn, but Geron is still running five phase 2 clinical trials and only had $122 million in the bank at the end of the second quarter.

Getting cash for the program should be the No. 1 priority for investors. If you own Geron at this point, it should primarily be because you have confidence in the cancer program.

Of course, it's been a year and none of the big boys like GlaxoSmithKline (NYSE: GSK  ) , Pfizer (NYSE: PFE  ) , and Teva Pharmaceuticals (NYSE: TEVA  )  -- which all have varying degrees of stem cell programs -- have stepped up to purchase the assets. At some point, getting something, even from a podunk biotech, is better than nothing from a shareholder's perspective.

It's going to take awhile to get rich owning Geron's stock, but that's true of most stocks. The Motley Fool has a new free report, "3 Stocks That Will Help You Retire Rich" with three suggestions to help put you on the road to riches now. Click here now to claim your free copy.

Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2066646, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:10:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
BTX $3.57 Down -0.01 -0.28%
BioTime CAPS Rating: *
GERN $2.12 Up +0.03 +1.44%
Geron CAPS Rating: ***
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
TEVA $44.00 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****